Lantern Pharma Inc. (LTRN) — SEC Filings
Lantern Pharma Inc. (LTRN) — 22 SEC filings. Latest: 8-K (Apr 10, 2026). Includes 10 8-K, 6 10-Q, 2 DEF 14A.
View Lantern Pharma Inc. on SEC EDGAR
Overview
Lantern Pharma Inc. (LTRN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 10, 2026: Lantern Pharma Inc. filed an 8-K on April 10, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes various exhibits, such as the 8-K form itself and supplemental graphical information, indicating a disclosure event on April
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 19 neutral, 3 mixed. The dominant filing sentiment for Lantern Pharma Inc. is neutral.
Filing Type Overview
Lantern Pharma Inc. (LTRN) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 1 10-K, 1 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of LTRN's 20 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$4,177,423 |
| Cash Position | $8,389,486 |
| Total Assets | $13,626,810 |
Key Executives
- Aaron Glenn
- Louis Fletcher
Industry Context
Lantern Pharma operates in the highly competitive biotechnology and pharmaceutical sector, focusing on oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Lantern are increasingly leveraging AI and advanced technologies, such as ADCs, to accelerate drug discovery and improve treatment efficacy.
Top Tags
sec-filing (4) · 10-Q (4) · financials (4) · filing (3) · corporate-governance (3) · pharmaceuticals (3) · financial-reporting (2) · Biotechnology (2) · shareholder-vote (2) · Proxy Statement (2)
Executive Compensation
From the most recent DEF 14A filing (Aug 8, 2025):
- Not Disclosed — Director Nominee: $0
- Not Disclosed — Executive Officer: $0
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0001763950 | Identifies Lantern Pharma Inc. in SEC filings. |
| SEC Accession Number | 0001493152-26-016047 | Unique identifier for this specific 8-K filing. |
| Net Loss | $4,177,423 | for the three months ended September 30, 2025, an improvement from $4,505,697 in 2024 |
| Research and Development Expenses | $8,769,305 | for the nine months ended September 30, 2025, a decrease from $11,856,169 in 2024 |
| Cash and Cash Equivalents | $8,389,486 | as of September 30, 2025, an increase from $7,511,079 at December 31, 2024 |
| Marketable Securities | $3,973,090 | as of September 30, 2025, a significant decrease from $16,501,984 at December 31, 2024 |
| Total Stockholders' Equity | $9,586,838 | as of September 30, 2025, a decrease from $21,187,774 at December 31, 2024 |
| Common Shares Outstanding | 11,040,219 | as of September 30, 2025, an increase from 10,784,725 at December 31, 2024 |
| Total Assets | $13,626,810 | as of September 30, 2025, a decrease from $25,571,792 at December 31, 2024 |
| Working Capital | $12.32M | as of June 30, 2025 |
| Net Loss Per Share | $0.82 | for six months ended June 30, 2025, improved from $0.97 in 2024 |
| Total Operating Expenses | $9.43M | for six months ended June 30, 2025, a 15.4% decrease from $11.14M in 2024 |
| Number of directors | 6 | Proposed for election to the Board of Directors |
| Number of repricings | 1 | Proposed one-time repricing of stock options |
| Fiscal year | 2025 | For which EisnerAmper LLP is proposed as auditor |
Frequently Asked Questions
What are the latest SEC filings for Lantern Pharma Inc. (LTRN)?
Lantern Pharma Inc. has 22 recent SEC filings from Feb 2024 to Apr 2026, including 10 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LTRN filings?
Across 22 filings, the sentiment breakdown is: 19 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Lantern Pharma Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lantern Pharma Inc. (LTRN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lantern Pharma Inc.?
Key financial highlights from Lantern Pharma Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LTRN?
The investment thesis for LTRN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lantern Pharma Inc.?
Key executives identified across Lantern Pharma Inc.'s filings include Aaron Glenn, Louis Fletcher.
What are the main risk factors for Lantern Pharma Inc. stock?
Of LTRN's 20 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Lantern Pharma Inc.?
Forward guidance and predictions for Lantern Pharma Inc. are extracted from SEC filings as they are enriched.